Unichem Laboratories reported a consolidated net profit of ₹41.47 crore for the quarter ended June 30, 2026, marking a significant turnaround from the net loss of ₹10.47 crore recorded in the corresponding quarter of FY25. The profitability shift was primarily driven by a 20.1% year-on-year increase in revenue from operations, which stood at ₹632.62 crore compared to ₹526.60 crore in Q1FY25. This revenue growth, coupled with effective cost management, resulted in an EBITDA margin expansion to 11% from 4.3% in the prior year period, signaling improved operational efficiency within the pharmaceutical segment.

The Board of Directors approved the unaudited consolidated and standalone financial statements during a meeting held on August 11, 2026. The results were reviewed by N. A. Shah Associates LLP, the statutory auditors, who issued an unmodified conclusion pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The standalone results also reflected this positive trend, with the company reporting a profit after tax of ₹5.53 crore, contrasting with a loss of ₹1.85 crore in the previous year's quarter.

Financial Performance Highlights

The following table summarises key consolidated financial metrics for the quarter alongside prior year comparatives and the full year ended March 2026:

Consolidated total income reached ₹648.23 crore, aided by other income rising to ₹15.61 crore from ₹6.82 crore in the prior year period. Total expenses increased moderately by 10.5% to ₹599.24 crore, indicating effective cost management despite higher operational volumes. Key expense components included cost of materials consumed at ₹190.02 crore and employee benefits expense at ₹103.31 crore.

Standalone Results and Subsidiary Contributions

On a standalone basis, Unichem Laboratories reported revenue from operations of ₹366.27 crore, a slight decline from ₹384.25 crore in Q1FY25. However, the entity turned profitable with a net profit of ₹5.53 crore, up from a loss of ₹1.85 crore. Standalone earnings per share stood at ₹0.79, compared to a loss of ₹0.26 per share in the previous year.

The auditor's report noted that subsidiaries Niche Generics Limited (UK) and Unichem Pharmaceuticals (USA), Inc. contributed significantly to the group's performance. These entities reported combined revenues of ₹470.28 crore and a net profit of ₹12.39 crore for the quarter. Other overseas subsidiaries, including entities in South Africa, Brazil, and China, contributed ₹23.59 crore in revenues. Additionally, during the quarter, the company invested USD 80,000 (equivalent to ₹0.76 crore) towards redeemable preference shares in its wholly owned subsidiary, Unichem (China) Pvt Ltd.

What the Numbers Show

The divergence between consolidated and standalone performance highlights the critical role of international operations in Unichem's profitability model. While the Indian parent entity saw flat revenue growth, the consolidated figures reflect strong international demand, particularly from its UK and US subsidiaries. The sharp expansion in EBITDA margin — from 4.3% to 11% — further underscores improved operating leverage across the group.

Notably, there were no exceptional items impacting the current quarter's bottom line, contrasting with the prior year's accounting adjustments related to European Commission fines and labor code provisions. Management continues to monitor developments pertaining to the New Labour Codes, which had resulted in a one-time provision of ₹15.40 crore in the previous fiscal year. The company also settled a European Commission fine demand of Euro 19.55 million in October 2025, with the interest component recognised as an exceptional item in FY26. No current tax charge was levied for the period due to the set-off of unabsorbed tax depreciation and business losses.

Unichem Laboratories disclosed on July 29, 2026, that the Additional Commissioner, Central Goods & Services Tax (CGST), (Appeals), Dehradun, has partially allowed its appeal concerning the disallowance of GSTR TRAN 1 credit. The order resulted in a demand of Rs 10,59,354 plus interest under Section 50 of the CGST Act, 2017. This development follows an earlier intimation dated January 27, 2025, regarding the ongoing dispute over input tax credit eligibility.

The regulatory action stems from an initial order by the Assistant Commissioner, CGST Division, Dehradun, which had disallowed TRAN 1 credit amounting to Rs 73,02,757 under Section 140(3) of the CGST Act, 2017. The original order also invoked Sections 74 and 122 of the Act for the same amount. Unichem Laboratories filed an appeal against this decision, leading to the recent partial allowance by the appellate authority.

Regulatory Details

The company received the direction from the authority on July 28, 2026, after 3:00 p.m., triggering disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The specific nature of the contravention alleged is the partial disallowance of GSTR TRAN 1 credit.

Financial Impact and Next Steps

Unichem Laboratories stated that the order will have no material impact on its financial, operational, or other activities. The company noted that it will take appropriate steps, including filing a further appeal against the said order within prescribed timelines, based on legal advice. The disclosure was made pursuant to Para (A) of Part (A) of Schedule III to Regulation 30 of the SEBI LODR Regulations, 2015.

What the Numbers Show

The reduction in the disputed amount from Rs 73,02,757 to Rs 10,59,354 indicates that the appellate authority accepted a significant portion of Unichem Laboratories' claim for GSTR TRAN 1 credit. Despite the remaining liability and associated interest, the company's assertion of no material financial impact suggests the revised demand is negligible relative to its overall balance sheet strength.